Shares of Trevena Inc (NASDAQ:TRVN) have been given an average recommendation of “Buy” by the nine analysts that are presently covering the firm, MarketBeat.com reports. Nine analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have covered the stock in the last year is $15.00.

Several brokerages recently issued reports on TRVN. Needham & Company LLC restated a “buy” rating and issued a $14.00 price objective on shares of Trevena in a report on Wednesday, November 11th. Wedbush restated an “outperform” rating and issued a $20.00 price objective on shares of Trevena in a report on Tuesday, November 17th. Zacks Investment Research lowered shares of Trevena from a “buy” rating to a “hold” rating in a report on Thursday, October 29th. Finally, Brean Capital began coverage on shares of Trevena in a report on Thursday, October 29th. They issued a “buy” rating on the stock.

Shares of Trevena (NASDAQ:TRVN) opened at 7.28 on Wednesday. Trevena has a 52-week low of $4.71 and a 52-week high of $13.57. The stock’s market capitalization is $369.58 million. The firm’s 50 day moving average is $9.07 and its 200 day moving average is $9.33.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.10. Equities analysts expect that Trevena will post ($1.11) earnings per share for the current year.

In other Trevena news, CMO David Soergel sold 27,217 shares of Trevena stock in a transaction dated Thursday, December 10th. The stock was sold at an average price of $10.55, for a total value of $287,139.35. Following the completion of the transaction, the chief marketing officer now directly owns 1,750 shares of the company’s stock, valued at approximately $18,462.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

A hedge fund recently bought a new stake in Trevena stock. Jennison Associates acquired a new position in Trevena Inc (NASDAQ:TRVN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 700,000 shares of the biopharmaceutical company’s stock, valued at approximately $7,245,000. Jennison Associates owned about 1.38% of Trevena at the end of the most recent reporting period.

Trevena Inc. (NASDAQ:TRVN) is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: TRV130, a small molecule G protein biased ligand at the mu-opioid receptor to treat patients experiencing moderate to severe acute pain where IV administration is preferred; TRV734, a small molecule G protein biased ligand at the mu-opioid receptor to treat moderate to severe acute and chronic pain, and TRV027, a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R), inhibiting G protein signaling and activating b-arrestin signaling. The Company has also identified a new product candidate, TRV250, a small molecule G protein biased ligand of the delta-opioid receptor program focused on central nervous system (CNS).

12 Month Chart for NASDAQ:TRVN

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Trevena Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc and related companies with MarketBeat.com's FREE daily email newsletter.